ZyVersa Therapeutics, Inc. (ZVSA) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

ZyVersa Therapeutics, Inc.

ZVSA

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

2M

Biotechnology

Next Earning date - 12 Nov 2024

2M

Biotechnology

Next Earning date - 12 Nov 2024

2.32USD

-0.01 ( -0.43%)

Relative Strenght

2

Volume Buzz

-88%

Earning Acce

Yes

Dist 52w H.

95%

Quote Panel

Updated October 12, 2024

1W 2.20 % 1M 6.42 % 3M -47.39 % 1Y -94.89 %

Key Metrics

Market Cap
2.49M
Shares Outstanding
1.07M
Share in Float
1.07M
Dividende
0

Earning Date
12 Nov 2024
Price Target
2.32
Average Volume
82006
Beta
0.637

Range
2.08-47.25
Industry
Biotechnology
Website
https://www.zyversa.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

159.75x

P/S Ratio

0.22x

P/B Ratio

0.0

Debt/Equity

-139944.8%

Net Margin

$1163.4

EPS

How ZVSA compares to sector?

P/E Ratio

Relative Strength

ZVSA

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

0

$46.20

-1296%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.41
vs -0.09

Q4.22

N/A

-18.45
vs -0.20

Q1.23

N/A

-0.39
vs -0.18

Q2.23

N/A

-1458.04
vs -0.18

Q3.23

N/A

-31.47
vs -0.41

Q4.23

N/A

-13.68
vs -18.45

Q1.24

N/A

-4.53
vs -0.39

Q2.24

N/A

-3.31
vs -1458.04

Q3.24

N/A

-1.60
vs -31.47

Q4.24

N/A

-1.80
vs -13.68

Sales Growth

YoY

Current

Estimates

Q1.22

NA

NA vs NA

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

15.6K vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Return on Equity

QoQ

Q3.22

+32%

0.32
vs 0.12

Q4.22

-5%

-0.05
vs 0.32

Q1.23

-4%

-0.04
vs -0.05

Q2.23

-391%

-3.91
vs -0.04

Q3.23

-15%

-0.15
vs -3.91

Q4.23

-120%

-1.20
vs -0.15

Q1.24

-25%

-0.25
vs -1.20

Q2.24

-32%

-0.32
vs -0.25

Institutionnal Ownership

Earnings Growth

Latest News

ZVSA

globenewswire.com

7 hours ago

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZVSA

globenewswire.com

7 hours ago

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZVSA

globenewswire.com

7 hours ago

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ZVSA

globenewswire.com

7 hours ago

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

ZVSA

globenewswire.com

11 hours ago

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

ZVSA

globenewswire.com

16 hours ago

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

New Feature Coming Soon, Stay Tuned!

Shape

Shape